Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results | Nature Medicine nature.com/articles/s4159…

🆕🗞️Hot off the press! Nature Medicine #KRAS Vaccine💉for patients with RAS➕cancers🎯. Benefit➡️durable.🙌🏽 More to come with the randomized study📚✔️! Opens to doors to off the shelf vaccine for so many patients with KRAS/NRAS mutations. OncoAlert 🔗nature.com/articles/s4159…

Prolonged chimeric antigen receptor-T apheresis to infusion time is associated with inferior outcomes in diffuse large B-cell lymphoma British Journal of Haematology share.google/nDjFlZaAivN8fh…

CircRNA-based, non-integrated, in vivo panCAR-mediated B cell immune resetting in mouse models and non-human primates biorxiv.org/content/10.110… #biorxiv_immuno

Dr. Brad Haverkos CU Anschutz Division of Hematology contributed to a CIBMTR study of CD19 CAR-T for PMBCL, now published AmericanJournalofHematology. Two-year PFS 59% and two-year OS 81%, with two-year cumulative incidence of relapse at 36%. #lymsm #tcellrx

I was lucky to lead this CIBMTR analysis just published in AmericanJournalofHematology 👇 onlinelibrary.wiley.com/share/author/4… 🔑 findings: 💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS

Ex vivo β-globin base-edited hematopoietic stem cells retain multilineage long-term engraftment potential upon autologous transplantation in NHPs science.org/doi/10.1126/sc… Gregory Newby Hans-Peter Kiem Science Translational Medicine

HIV-1 viremia not suppressed by effective antiretroviral therapy can be driven by proviruses in CD4+ T cells reactive to autologous antigens science.org/doi/10.1126/sc…

Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work led to this moment, made possible by an amazing team! 🧵 🪡 cell.com/cancer-cell/fu…

『Outcomes of PLAT-02 and PLAT-03: evaluating CD19 CAR T-cell therapy and CD19-expressing T-APC support in pediatric B-ALL』 Blood August 14 2025 短縮型CD19を発現するT細胞抗原提示細胞T-APC T-APC投与でCAR Tの持続性が向上（P = .03） 早期CAR消失率低下（T-APCあり：20%、なし：57%）

1/ My first time tweeting preprint since March 2020... Analysis of >600 CAR-T recipients from two 🇺🇸 time zones. Earlier infusions (before 3pm) seem to be better! 😳 ⚠️ Still needs peer review. I don't see breakdown of specific CAR products by ≤2:59p vs ≥3:00p, for instance.

1/ New Blood Advances treasure trove of 🇩🇪 🇺🇸 data about bridging before CAR-T in #MMsm. Bigger is not better when it comes to bridging using chemotherapy... Worse post-CAR-T efficacy (unsurprising: tumor biology as confounder) but also clearly worse cytopenias & infections!

This comes from our center, and thus as it includes my patients, I have many hypotheses :) The vast majority if not all of these patients got CART inpatient, being direct admitted the night before CART infusion tentatively planned for 9-11 AM. Delays outside that window usually

Regulatory T cell therapy promotes TGF-β and IL-6-dependent pro-inflammatory Th17 cell generation by reducing IL-2 Nature Communications nature.com/articles/s4146…

Purine nucleobases enhance CD8+ T cell effector function biorxiv.org/content/10.110… #biorxiv_immuno

Preprint: Autologous genome-edited hematopoietic stem cells correct Gaucher disease (achieved with ~ 3% edited allele engraftment) and establish a platform for clinical translation researchsquare.com/article/rs-712…

New in Cell Reports Medicine! 📢 A collaboration between the Berger Lab, Carl June, & Mark O'Hara, assessed the safety and feasibility of intravenous and local administration of anti-mesothelin CAR T cells in patients with advanced #PDAC. bit.ly/4fEx38e

The website and the report for the German National Strategy for Gene- and Cell-based Therapies is now available: nationale-strategie-gct.de/en/ If you want to know how Germany will develop these key therapies.

A phase 2 academic clinical trial of CD19 CAR T cells demonstrates durable remissions with a 1-year LFS in low disease burden groups of >90%. ow.ly/5goJ50WGPvL #clinicaltrialsandobservations #immunobiologyandimmunotherapy #lymphoidneoplasia #pediatrichematology

Lisocabtagene Maraleucel Versus Standard of Care for Second-Line Relapsed/Refractory Large B-Cell Lymphoma: 3-Year Follow-Up From the Randomized, Phase III TRANSFORM Study. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…